The Effect of Quercetin in Sarcoidosis
Launched by MAASTRICHT UNIVERSITY MEDICAL CENTER · Nov 21, 2006
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • clinical diagnosis of sarcoidosis with emphasize on pulmonary sarcoidosis
- • no smoking
- • no treatment
- Exclusion Criteria:
- • clinical diagnosis (and treatment) of other diseases
- • symptoms of sarcoidosis in other organs besides the lung
- • use of food supplements or vitamins
About Maastricht University Medical Center
Maastricht University Medical Center (MUMC+) is a leading academic medical center in the Netherlands, renowned for its commitment to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, MUMC+ integrates cutting-edge scientific inquiry with clinical practice, focusing on a wide range of medical disciplines. The center emphasizes collaboration among multidisciplinary teams, fostering an environment that promotes excellence in patient care and the translation of research findings into clinical applications. MUMC+ is dedicated to improving health outcomes and enhancing quality of life through rigorous clinical investigations and the development of novel therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Maastricht, , Netherlands
Patients applied
Trial Officials
Aalt Bast, PhD
Study Chair
Maastricht University
Agnes W Boots, PhD
Principal Investigator
Maastricht University
Guido R Haenen, PhD
Study Director
Maastricht University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials